Literature DB >> 15050736

Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion.

Kenichiro Ishii1, Takashi Otsuka, Kazuhiro Iguchi, Shigeyuki Usui, Hajime Yamamoto, Yoshiki Sugimura, Kazuhiro Yoshikawa, Simon W Hayward, Kazuyuki Hirano.   

Abstract

Prostate-specific antigen (PSA), which is used as a marker for the diagnosis and monitoring of prostate cancer, is a kallikrein protease which could potentially play a role in human prostate cancer cell invasion. Zinc ions are effective inhibitors of a number of proteases. The enzymatic activity of purified PSA was strongly inhibited by Zn(2+). The ability of LNCaP cells which express and secrete PSA to invade Matrigel was strongly suppressed by Zn(2+) at a concentration similar to that inhibiting the activity of purified PSA. Zn(2+) effectively inhibited the degradation of Matrigel by purified PSA. These results suggest that Zn(2+) in human prostate may suppress the invasion and metastasis of prostate cancer cells through the regulation of the proteolytic activity of PSA. Loss of inhibition of the proteolytic activity of PSA by Zn(2+) in prostate tumors could contribute to invasion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15050736     DOI: 10.1016/j.canlet.2003.09.029

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  18 in total

Review 1.  New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.

Authors:  Nashmil Emami; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

2.  Decreased zinc and downregulation of ZIP3 zinc uptake transporter in the development of pancreatic adenocarcinoma.

Authors:  Leslie C Costello; Bernard A Levy; Mohamed M Desouki; Jing Zou; Omar Bagasra; Leslie A Johnson; Nader Hanna; Renty B Franklin
Journal:  Cancer Biol Ther       Date:  2011-08-15       Impact factor: 4.742

Review 3.  Zinc as an anti-tumor agent in prostate cancer and in other cancers.

Authors:  Renty B Franklin; Leslie C Costello
Journal:  Arch Biochem Biophys       Date:  2007-03-16       Impact factor: 4.013

4.  Missing Selectivity of Targeted 4β-Phorbol Prodrugs Expected to be Potential Chemotherapeutics.

Authors:  Ilari Tarvainen; Tomáš Zimmermann; Pia Heinonen; Maria Helena Jäntti; Jari Yli-Kauhaluoma; Virpi Talman; Henrik Franzyk; Raimo K Tuominen; Søren Brøgger Christensen
Journal:  ACS Med Chem Lett       Date:  2019-12-23       Impact factor: 4.345

Review 5.  Zinc and zinc transporters in prostate carcinogenesis.

Authors:  Vladimir Kolenko; Ervin Teper; Alexander Kutikov; Robert Uzzo
Journal:  Nat Rev Urol       Date:  2013-03-12       Impact factor: 14.432

6.  Overexpression of the zinc uptake transporter hZIP1 inhibits nuclear factor-kappaB and reduces the malignant potential of prostate cancer cells in vitro and in vivo.

Authors:  Konstantin Golovine; Peter Makhov; Robert G Uzzo; Tavis Shaw; David Kunkle; Vladimir M Kolenko
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

7.  Thiophilic-interaction chromatography of enzymatically active tissue prostate-specific antigen (T-PSA) and its modulation by zinc ions.

Authors:  A K Satheesh Babu; M A Vijayalakshmi; Gary J Smith; Kailash C Chadha
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-12-04       Impact factor: 3.205

8.  Suppression of metallothionein 3 gene expression by androgen in LNCaP prostate cancer cells.

Authors:  Takashi Otsuka; Aki Hamada; Kazuhiro Iguchi; Shigeyuki Usui; Kazuyuki Hirano
Journal:  Biomed Rep       Date:  2013-05-17

Review 9.  The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots.

Authors:  Leslie C Costello; Renty B Franklin
Journal:  Mol Cancer       Date:  2006-05-15       Impact factor: 27.401

10.  hZip2 and hZip3 zinc transporters are down regulated in human prostate adenocarcinomatous glands.

Authors:  Mohamed M Desouki; Joseph Geradts; Beatrice Milon; Renty B Franklin; Leslie C Costello
Journal:  Mol Cancer       Date:  2007-06-05       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.